Table 2.

Clinical trials with anti-OX40

Year	Drug	Phase	Company	Type	Objective	Clinical trial.gov identifier
2012	OX40 mAb	I	Providence Health & Services	Anti-OX40	OX40 in patients with advanced cancer	NCT01644968
2014	Anti-OX40	II	Ludwig Institute for Cancer Research	Anti-OX40	Combining a mouse monoclonal anti-OX40 and Ipilimumab in metastatic melanoma patients	NCT01689870
2014	MEDI6469	I	Providence Health & Services	Anti-OX40	MEDI6469 applied pre-surgical resection patients with oral, head and neck squamous-cell carcinoma	NCT02274155
2014	Pf-04518600	I	Pfizer	OX40 Agonist	Pf-04518600 and Pf-05082566 in selected partially advanced or metastatic cancers	NCT02315066
2015	MOXR0916	I	Genentech, Inc.	Anti-OX40	MOXR0916 and atezolizumab (anti-PD-L1) in locally advanced or metastatic tumors	NCT02410512
2015	MEDI6469	I	Providence Health & Services	Anti-OX40	MEDI6469 in patients with metastatic colorectal cancer	NCT02559024
2017	PF-04518600	II	University of Southern California	Anti-OX40	PF-04518600 in combination with axitinib versus axitinib in metastatic renal cell carcinoma and exposed to immune checkpoint inhibitor	NCT03092856
2017	MEDI0562	I	Providence Health & Services	Anti-OX40	MEDI0562 administered pre-surgical resection in melanoma or squamous cell carcinoma	NCT03336606
2018	BMS 986178	I	Ronald Levy	Anti-OX40	Intratumoral injection of SD-101 and BMS-986178 combined with local radiation in patients with low-grade B cell lymphomas	NCT03410901